Opinion

Video

FDA-Approved Therapies for Fibromyalgia

An expert rheumatologist reviews the efficacy and safety of the 3 FDA-approved therapies for treating fibromyalgia—pregabalin, duloxetine, and milnacipran.

This is a video synopsis/summary of a panel discussion involving Philip J. Mease, MD.

Effective management of fibromyalgia involves a spectrum of medications targeting symptoms like sleep disturbances and pain. Tricyclic antidepressants, utilized historically, demonstrated efficacy in improving sleep and ameliorating pain. However, their limited dosage capacity due to adverse events prompted the exploration of newer alternatives. Presently, 3 FDA-approved medications stand out for fibromyalgia treatment. Pregabalin, a notable contender, functions by limiting neuropeptides in the ascending nociceptive pathway, including GABA and substance P, which are excessively present in the central nervous system.

Additionally, 2 drugs, duloxetine and milnacipran, have gained approval for their ability to enhance serotonin and norepinephrine signaling in the descending pathways of the central nervous system. This dual action not only diminishes pain but also brings about improvements in sleep and fatigue. Significantly, these newer medications boast better tolerance compared to their tricyclic predecessors, marking a positive stride in fibromyalgia pharmacotherapy.

An intriguing study explored the combination of milnacipran and pregabalin, revealing an additive effect without an increase in adverse events. This finding suggests a potential avenue for combination therapy to enhance therapeutic benefits while minimizing unwanted effects. Precautions, however, are essential, particularly concerning potential interactions with antidepressants. Excessive serotonin effects may arise when combining these medications, necessitating a collaborative approach with other healthcare providers. This underscores the importance of interdisciplinary communication to tailor treatments and optimize patient care. In essence, these medications play a pivotal role in addressing the complex challenges faced by fibromyalgia patients, addressing not only pain but also encompassing improvements in physical function, cognition, fatigue, and overall patient well-being.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.